OR WAIT null SECS
April 11, 2023
A document signed by members of more than 400 companies and investment firms decries the decision made by a federal judge concerning mifepristone, a medication used in abortions.
April 10, 2023
Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?
April 07, 2023
The agency is dealing with high demand for staff because of a surge in the development of cell and gene therapies.
If approved, Johnson & Johnson would pay $8.9 billion to resolve all current and future claims in its ongoing talc litigation.
FDA aims to address mounting criticisms of its accelerated approval pathway.
Lonza and ABL Bio are collaborating on the development and manufacture of bispecific antibody product.
NextPharma has acquired a leading European chewable tablets manufacturing site from Takeda in Asker, Norway.
April 05, 2023
Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.
April 04, 2023
A CPHI North America panel discussion forewarns that CDMO supply chains are potentially the biggest single risk to product resilience.
April 02, 2023
What can we take away from Pfifzer's acquisition of Seagen?
